ArticleOncogene2007
Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage.
Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Golgi Complex: A Signaling Hub in Cancer.Cells · 2022Review
- RAS-mediated tumor stress adaptation and the targeting opportunities it presents.Disease models & mechanisms · 2022Article
- Profiling of human lymphocytes reveals a specific network of protein kinases modulated by endurance training status.Scientific reports · 2020Article
- RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation.Nature communications · 2018Article
- Review
- Physiological Signaling and Structure of the HGF Receptor MET.Biomedicines · 2014Review
- Nuclear factor-κB signaling pathway is involved in phospholipase Cε-regulated proliferation in human renal cell carcinoma cells.Molecular and cellular biochemistry · 2014Article
- Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Targeting the hepatocyte growth factor-cMET axis in cancer therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Article
- Stress- and Rho-activated ZO-1-associated nucleic acid binding protein binding to p21 mRNA mediates stabilization, translation, and cell survival.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Raf kinases in cancer-roles and therapeutic opportunities.Oncogene · 2011Review
- Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer.Cancer causes & control : CCC · 2011Review
- Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice.Cancers · 2010Article
- Comparison of human chromosome 19q13 and syntenic region on mouse chromosome 7 reveals absence, in man, of 11.6 Mb containing four mouse calcium-sensing receptor-related sequences: relevance to familial benign hypocalciuric hypercalcaemia type 3.European journal of human genetics : EJHG · 2010Article
- Role of Src signal transduction pathways in scatter factor-mediated cellular protection.The Journal of biological chemistry · 2009Article
- Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
- Anticancer Effect of AntiMalarial Artemisinin Compounds.Annals of medical and health sciences researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Scatter factor (SF) (hepatocyte growth factor) is a pleiotrophic cytokine that accumulates within tumors in vivo and protects tumor cells against cytotoxicity and apoptosis due to DNA damaging agents in vitro. Previous studies have established that SF-mediated cell protection involves antiapoptotic signaling from its receptor (c-Met) to PI3 kinase --> c-Akt --> Pak1 (p21-activated kinase -1) --> NF-kappaB (nuclear factor-kappa B). Here, we found that Ras proteins (H-Ras and R-Ras) enhance SF-mediated activation of NF-kappaB and protection of DU-145 and MDCK (Madin-Darby canine kidney) cells against the topoisomerase IIalpha inhibitor adriamycin. Studies of Ras effector loop mutants and their downstream effectors suggest that Ras/PI3 kinase and Ras/Raf1 pathways contribute to SF stimulation of NF-kappaB signaling and cell protection. Further studies revealed that Raf1 positively regulates the ability of SF to stimulate NF-kappaB activity and cell protection. The ability of Raf1 to stimulate NF-kappaB activity was not due to the classical Raf1 --> MEK1/2 --> ERK1/2 pathway. However, we found that a MEK3/6 --> p38 pathway contributes to SF-mediated activation of NF-kappaB. In contrast, RalA, a target of the Ras/RalGDS pathway negatively regulated the ability of SF to stimulate NF-kappaB activity and cell protection. Ras, Raf1 and RalA modulate SF stimulation of NF-kappaB activity, in part, by regulating IkappaB kinase (IKK)-beta kinase activity. These findings suggest that Ras/Raf1/RalA pathways may converge to modulate NF-kappaB activation and SF-mediated survival signaling at the IKK complex and/or a kinase upstream of this complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.